Bruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.
Follow BRKR
Bruker Corporation (BRKR) EV/Sales
As of 16 October 2026, Bruker Corporation (BRKR) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from 1.6× (October 2015) to 6.2× (September 2021); the current reading is higher than 42% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | (19.74%) |
| FY2024 | 3.2× | (17.61%) |
| FY2023 | 3.8× | (10.38%) |
| FY2022 | 4.3× | (19.55%) |
| FY2021 | 5.3× | 25.70% |
| FY2020 | 4.2× | 9.18% |
| FY2019 | 3.9× | 57.48% |
| FY2018 | 2.5× | (19.96%) |
| FY2017 | 3.1× | 46.07% |
| FY2016 | 2.1× | (11.83%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.1× | 51.78% |
| Mar 2026 | 2.0× | (19.85%) |
| Dec 2025 | 2.5× | 31.29% |
| Sep 2025 | 1.9× | (22.52%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.5× |
| BRKR Bruker Corporation | 2.9× |
| PODD Insulet Corporation compare | 3.3× |
| GMED Globus Medical, Inc. compare | 3.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| HAE Haemonetics Corporation compare | 4.7× |
| PEN Penumbra, Inc. compare | 8.0× |
| GKOS Glaukos Corporation compare | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)